Follow
Sheena Smith
Sheena Smith
Head of Program Management, Vector BioPharma
Verified email at vectorbiopharma.com
Title
Cited by
Cited by
Year
Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains
DT Harris, MV Hager, SN Smith, Q Cai, JD Stone, P Kruger, M Lever, ...
The Journal of Immunology 200 (3), 1088-1100, 2018
1532018
Yeast lipin 1 orthologue pah1p regulates vacuole homeostasis and membrane fusion
T Sasser, QS Qiu, S Karunakaran, M Padolina, A Reyes, B Flood, S Smith, ...
Journal of Biological Chemistry 287 (3), 2221-2236, 2012
1102012
Changing the peptide specificity of a human T-cell receptor by directed evolution
SN Smith, Y Wang, JL Baylon, NK Singh, BM Baker, E Tajkhorshid, ...
Nature communications 5 (1), 5223, 2014
442014
Residual feed intake of Angus beef cattle divergently selected for feed conversion ratio
SN Smith, ME Davis, SC Loerch
Livestock Science 132 (1-3), 41-47, 2010
362010
NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity
N Kirchhammer, MP Trefny, M Natoli, D Brücher, SN Smith, F Werner, ...
Science translational medicine 14 (653), eabm9043, 2022
342022
T cell receptor engineering and analysis using the yeast display platform
SN Smith, DT Harris, DM Kranz
Yeast Surface Display: Methods, Protocols, and Applications, 95-141, 2015
302015
An engineered switch in T cell receptor specificity leads to an unusual but functional binding geometry
DT Harris, NK Singh, Q Cai, SN Smith, CW Vander Kooi, E Procko, ...
Structure 24 (7), 1142-1154, 2016
292016
Engineering t cell receptors
SN Smith, DM Kranz
US Patent App. 14/417,434, 2015
272015
iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy
D Brücher, N Kirchhammer, SN Smith, J Schumacher, N Schumacher, ...
Molecular Therapy-Methods & Clinical Development 20, 572-586, 2021
242021
The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody
SN Smith, R Schubert, B Simic, D Brücher, M Schmid, N Kirk, PC Freitag, ...
Proceedings of the National Academy of Sciences 118 (21), e2017925118, 2021
202021
Plasticity in the contribution of T cell receptor variable region residues to binding of peptide–HLA-A2 complexes
SN Smith, D Sommermeyer, KH Piepenbrink, SJ Blevins, H Bernhard, ...
Journal of molecular biology 425 (22), 4496-4507, 2013
192013
Engineered high-affinity human t cell receptors
SN Smith, DT Harris, DM Kranz, PD Greenberg, TM Schmitt
US Patent 10,344,075, 2019
92019
Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness
D Brücher, V Franc, SN Smith, AJR Heck, A Plückthun
MAbs 12 (1), 1792084, 2020
82020
Engineered high-affinity human t cell receptors
SN Smith, DT Harris, DM Kranz
US Patent 10,023,625, 2018
72018
Targeted adenovirus-mediated transduction of human T cells in vitro and in vivo
PC Freitag, M Kaulfuss, L Flühler, J Mietz, F Weiss, D Brücher, J Kolibius, ...
Molecular Therapy-Methods & Clinical Development 29, 120-132, 2023
42023
CRISPR-clear imaging of melanin-rich B16-derived solid tumors
R Schubert, T Bae, B Simic, SN Smith, SH Park, G Nagy-Davidescu, ...
Communications Biology 6 (1), 370, 2023
22023
Successful IL-12 cancer immunotherapy requires NK cell-derived CCL5 for anti-tumor DC-T cell crosstalk
N Kirchhammer, MP Trefny, M Natoli
bioRxiv, 2021
22021
Engineering t cell receptors
SN Smith, DM Kranz
US Patent 11,384,133, 2022
12022
Engineered high-affinity human t cell receptors
SN Smith, DT Harris, DM Kranz
US Patent App. 17/586,652, 2022
2022
Adaptive anti-tumor immunity is orchestrated by a population of CCL5-producing tissue-resident NK cells
N Kirchhammer, MP Trefny, M Natoli, D Brücher, SN Smith, F Werner, ...
bioRxiv, 2021.05. 27.445981, 2021
2021
The system can't perform the operation now. Try again later.
Articles 1–20